Cytosorbents Corporation (CTSO)Healthcare | Medical Devices | Princeton, United States | NasdaqCM
4.11 USD
+1.05
(34.314%)
⇧
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 4.00 -0.11 (-0.110%) ⇩ (Oct. 16, 2026, 7:48 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:57 a.m. EDT
The investment case for Cytosorbents is currently broken by a severe disconnect between its historical valuation and its present reality. While the company possesses a unique technology in blood purification, the financial data reveals a business in distress: it is burning cash, generating negative operating margins, and has returned less than 16% of its book value over the last nine years. The stock has been decimated, dropping roughly 85% from its peak, and despite trading near its 52-week low, the fundamentals remain precarious with a negative return on equity and no path to profitability visible in the immediate term. Short-term, the price action shows weakness, trading well below its 50-day and 200-day averages, which confirms the downtrend. The lack of analyst coverage and the absence of a dividend yield further erode the safety margin. While insider buying provides a minor glimmer of hope, it is insufficient to counteract the structural decline in earnings and the heavy debt load relative to cash on hand. The statistical forecasting models are useless here due to extreme noise, and the options market offers no clear signal of a reversal. This remains a high-risk speculative vehicle where the probability of further downside outweighs the potential for a quick recovery until the company can demonstrate a return to positive cash flow. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.255644 |
| AutoARIMA | 0.312121 |
| AutoETS | 0.312712 |
| MSTL | 0.315145 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 94.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.116 |
| Excess Kurtosis | -1.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 11.856 |
| Market Cap | 12,951,026 |
| Forward P/E | Infinity |
| Beta | 1.37 |
| Profit Margins | -48.94% |
| Website | https://www.cytosorbents.com |
As of Oct. 10, 2026, 4:57 a.m. EDT: Options activity is sparse and lacks directional conviction. Put open interest is concentrated at strikes significantly out-of-the-money relative to the current price, suggesting speculative hedging or a 'long shot' bet on a crash rather than a protective floor. Call volume is negligible, indicating a lack of bullish positioning. Implied volatility is elevated on the nearest expiration, reflecting uncertainty, but the lack of meaningful flow suggests speculators are waiting for a catalyst rather than committing capital to a specific outcome.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7582353 |
| Address1 | 305 College Road East |
| All Time High | 1,975.0 |
| All Time Low | 2.84 |
| Ask | 5.06 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 78,080 |
| Average Daily Volume3 Month | 23,550 |
| Average Volume | 23,550 |
| Average Volume10Days | 78,080 |
| Beta | 1.368 |
| Bid | 3.09 |
| Bid Size | 2 |
| Book Value | -0.239 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.11 |
| Current Ratio | 0.655 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.6 |
| Day Low | 3.01 |
| Display Name | Cytosorbents |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,046,400 |
| Earnings Call Timestamp Start | 1,786,046,400 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -10,349,000 |
| Ebitda Margins | -0.27808002 |
| Enterprise To Ebitda | -3.665 |
| Enterprise To Revenue | 1.019 |
| Enterprise Value | 37,927,184 |
| Eps Forward | 0.0 |
| Eps Trailing Twelve Months | -5.8 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 732 329 8650 |
| Fifty Day Average | 5.7354 |
| Fifty Day Average Change | -1.6254001 |
| Fifty Day Average Change Percent | -0.28339785 |
| Fifty Two Week Change Percent | -75.823524 |
| Fifty Two Week High | 18.0 |
| Fifty Two Week High Change | -13.889999 |
| Fifty Two Week High Change Percent | -0.77166665 |
| Fifty Two Week Low | 2.84 |
| Fifty Two Week Low Change | 1.2700002 |
| Fifty Two Week Low Change Percent | 0.4471832 |
| Fifty Two Week Range | 2.84 - 18.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,155,043,800,000 |
| Float Shares | 2,771,899 |
| Forward Eps | 0.0 |
| Forward P E | Infinity |
| Free Cashflow | -3,508,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 129 |
| Fullday Change | 0.94000006 |
| Fullday Change Percent | 30.718958 |
| Fullday Price | 4.11 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.71606004 |
| Gross Profits | 26,649,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16253 |
| Held Percent Institutions | 0.25502002 |
| Implied Shares Outstanding | 3,151,101 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,788,825,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. |
| Long Name | Cytosorbents Corporation |
| Market | us_market |
| Market Cap | 12,951,026 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_628213 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -18,214,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 15,471,905 |
| Number Of Analyst Opinions | 2 |
| Open | 3.01 |
| Operating Cashflow | -9,147,000 |
| Operating Margins | -0.24582 |
| Phone | 732 329 8885 |
| Post Market Change | -0.11000013 |
| Post Market Change Percent | -2.676402 |
| Post Market Price | 4.0 |
| Post Market Time | 1,792,194,521 |
| Previous Close | 3.06 |
| Price Hint | 4 |
| Price To Book | -17.196653 |
| Price To Sales Trailing12 Months | 0.34799618 |
| Profit Margins | -0.48941 |
| Quick Ratio | 0.466 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.05 |
| Regular Market Change Percent | 34.3137 |
| Regular Market Day High | 4.6 |
| Regular Market Day Low | 3.01 |
| Regular Market Day Range | 3.01 - 4.6 |
| Regular Market Open | 3.01 |
| Regular Market Previous Close | 3.06 |
| Regular Market Price | 4.11 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 659,361 |
| Return On Assets | -0.17119 |
| Return On Equity | -3.36207 |
| Revenue Growth | 0.002 |
| Revenue Per Share | 11.856 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,151,101 |
| Shares Percent Shares Out | 0.039300002 |
| Shares Short | 123,890 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 115,309 |
| Short Name | Cytosorbents Corporation |
| Short Percent Of Float | 0.0427 |
| Short Ratio | 4.71 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CTSO |
| Target High Price | 80.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 47.5 |
| Target Median Price | 47.5 |
| Total Cash | 4,413,000 |
| Total Cash Per Share | 1.404 |
| Total Debt | 29,426,000 |
| Total Revenue | 37,216,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.92025 |
| Two Hundred Day Average Change | -5.81025 |
| Two Hundred Day Average Change Percent | -0.5856959 |
| Type Disp | Equity |
| Volume | 659,361 |
| Website | https://www.cytosorbents.com |
| Zip | 8,540 |